This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
249
One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Unnamed facility
Wenatchee, Washington, United States
Intraocular pressure (IOP)
Time frame: Day 5
Patient Comfort
Time frame: Days 1-4
Patient Satisfaction
Time frame: Day 5
Treatment Preference
Time frame: Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs